Company intelligence / Profile preview
Genecombio
- Ownership
- Private
- Development stage
- Phase 1
Overview
Genecombio Ltd. is a private biotechnology company founded in 2021 and headquartered in Shanghai, China. The company specializes in AAV-based gene therapies targeting rare neurological disorders such as Rett syndrome and spinal muscular atrophy type 2. Its lead programs include GCB‑001 and GCB‑002, both of which are advancing through early clinical development. The company's technology platform centers on adeno-associated virus vectors for targeted delivery of therapeutic genes such as MECP2.
- Therapeutic areas
- Neurology
- Modalities
- AAV based gene therapyBiological products
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Genecombio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genecombio.